MUMBAI, (IANS) – Pharma major Lupin Limited has said that it has launched Mirabegron extended-release tablets, 25 mg, in the US market, after having received approval from the Food and Drug ...
Overview Java backend roles in 2026 demand strong fundamentals plus expertise in modern frameworks like Spring Boot and ...
NEW DELHI: A wave of affordable generic versions of Ozempic and Wegovy (semaglutide) has rapidly captured around 20% of the nearly Rs 1,600 crore weight-loss market within days of launch, following ...
The rapid entry of semaglutide generics is beginning to weigh on the growth of Eli Lilly’s tirzepatide brand Mounjaro, even as the broader market expands, data from pharma market intelligence and data ...
As Asia grappled with the impact of the Iran war, a major pharmaceutical milestone quietly made the headlines. On March 20, the patent for semaglutide, the active ingredient in Novo Nordisk’s Ozempic ...
The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...
The decision, based on a Commerce Department review, highlights supply risks while leaving room for future action on generic drug imports The United States will not impose tariffs on generic medicines ...
March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...
The blockbuster weight loss drug sold as Ozempic and Wegovy will soon go generic in countries that are home to 40% of the world’s population, significantly lowering the price of a costly medicine that ...
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results